Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Defending Multidrug Masking in Psilocybin Trials, With Josh Woolley, MD, PhD

20 September 2026 · By · Wire by Fusion42

Published

20 September 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at hcplive.com →

◆ Verified

Fusion42 · 20 September 2026 · Fusion42 review

Josh Woolley, MD, PhD, advocates for the UMBRAA multidrug blinding framework in high-dose psilocybin trials to improve masking by using a complex multidrug comparator, arguing it creates comparable intoxication without delirium and addresses unmasking issues in placebo controls.

This Wire brief sits within Fusion42's coverage of Health.

◆ ◆ The Wire takeaway

You in psychedelic drug development face new chances to access better placebo controls with complex multidrug masking. This could make your trial data more credible but also demands navigating novel consent and regulatory acceptability hurdles.

◆ Coverage

1 source · 20 Sep 2026

◆ Related on Wire

◆ Topics

Healthpsilocybinclinical-trialsmaskingmultidrug-comparatorpsychedelic-research